Linda G.P. Schneider MD MBA, FAAFP

Family Medicine•Newport News, VA

Healthcare Research and Healthcare Policy

Medical Director TPMG Clinical Research

Join to View Full Profile

860 Omni Blvd.Ste 101Newport News, VA 23606
Phone+1 757-232-8836
Fax+1 757-310-6232

Education & Training

Old Dominion UniversityMBA, MBA, Healthcare Administration, 2000
Charleston Area Medical Center/CAMC Institute for Academic MedicineResidency, Family Medicine, 1979 - 1982
Eastern Virginia Medical SchoolClass of 1979

Certifications & Licensure

VA State Medical License 1983 - 2026
American Board of Family Medicine Family Medicine

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification NextGen Ambulatory EHR, NextGen Healthcare, 2012-2013

Clinical Trials

Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction (OCEAN(a)) - Outcomes Trial Start of enrollment: 2022 Dec 14
ACTIVE_NOT_RECRUITING
PHASE3
A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor Start of enrollment: 2023 Sep 27
ACTIVE_NOT_RECRUITING
PHASE3
A Study to Evaluate the Effect of Sodium Zirconium Cyclosilicate on Chronic Kidney Disease (CKD) Progression in Participants With CKD and Hyperkalaemia or at Risk of Hyperkalaemia Start of enrollment: 2021 Sep 30
TERMINATED
PHASE3
Management of LDL-cholesterol With Inclisiran + Usual Care Compared to Usual Care Alone in Participants With a Recent Acute Coronary Syndrome Start of enrollment: 2021 Jun 24
COMPLETED
PHASE3
Zibotentan and Dapagliflozin for the Treatment of CKD (ZENITH-CKD Trial) Start of enrollment: 2021 Apr 28
COMPLETED
PHASE2
Study to Investigate Efficacy, Safety, and Tolerability of Zibotentan/Dapagliflozin Compared to Dapagliflozin in Participants With Chronic Kidney Disease and High Proteinuria (ZENITH High Proteinuria) Start of enrollment: 2023 Nov 07
ACTIVE_NOT_RECRUITING
PHASE3
A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight Start of enrollment: 2022 Nov 01
ACTIVE_NOT_RECRUITING
PHASE3
EMPACT-MI: A Study to Test Whether Empagliflozin Can Lower the Risk of Heart Failure and Death in People Who Had a Heart Attack (Myocardial Infarction) Start of enrollment: 2020 Dec 16
COMPLETED
PHASE3
A Research Study of a New Medicine NNC0519-0130 in Healthy People, People With High Body Weight and People With Type 2 Diabetes. Start of enrollment: 2022 Apr 20
COMPLETED
PHASE1
A Study Evaluating the Safety and Efficacy of Hormone Replacement Therapy With ST-1891 Compared to Levothyroxine in Patients With Primary Hypothyroidism Start of enrollment: 2022 Apr 29
COMPLETED
PHASE2
EPIC-HR: Study of Oral PF-07321332/Ritonavir Compared With Placebo in Nonhospitalized High Risk Adults With COVID-19 Start of enrollment: 2021 Jul 16
Completed
Phase 2, Phase 3
Evaluation of Protease Inhibition for COVID-19 in Standard-Risk Patients (EPIC-SR). Start of enrollment: 2021 Aug 25
Terminated
Phase 2, Phase 3
A Study of a Potential Oral Treatment to Prevent COVID-19 in Adults Who Are Exposed to Household Member(s) With a Confirmed Symptomatic COVID-19 Infection Start of enrollment: 2021 Sep 09
Completed
Phase 2, Phase 3
Join now to see all